Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.

Trial Details

NCT ID
NCT07516093
Phase
PHASE3
Sponsor
Nurix Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • NX-5948
  • Pirtobrutinib
Locations (sample)
  • Macon, Georgia, United States|32.84069,-83.6324
  • Fort Wayne, Indiana, United States|41.1306,-85.12886
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Midland, Texas, United States|31.99735,-102.07791

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Confirmed diagnosis of CLL/SLL that meets iwCLL 2018 criteria for diagnosis and systemic treatment
  • Received at least 1 prior line of therapy for CLL/SLL that included a cBTKi and must have documented disease progression during treatment with, or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →